相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。PARP Inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies
J-m. Lee et al.
ANNALS OF ONCOLOGY (2014)
Serum angiopoietin-2 and soluble VEGFR-2 levels predict malignancy of ovarian neoplasm and poor prognosis in epithelial ovarian cancer
Hanna Sallinen et al.
BMC CANCER (2014)
Cancer Statistics, 2014
Rebecca Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2014)
Serum Interleukin-8 Reflects Tumor Burden and Treatment Response across Malignancies of Multiple Tissue Origins
Miguel F. Sanmamed et al.
CLINICAL CANCER RESEARCH (2014)
Emerging Role for Bevacizumab in Combination With Chemotherapy for Patients With Platinum-Resistant Ovarian Cancer
Joyce F. Liu et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial
Eric Pujade-Lauraine et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Incorporation of Pazopanib in Maintenance Therapy of Ovarian Cancer
Andreas du Bois et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Phase I/Ib Study of Olaparib and Carboplatin in BRCA1 or BRCA2 Mutation-Associated Breast or Ovarian Cancer With Biomarker Analyses
Jung-Min Lee et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2014)
Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study
Joyce F. Liu et al.
LANCET ONCOLOGY (2014)
Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial
Jonathan Ledermann et al.
LANCET ONCOLOGY (2014)
MRI biomarkers identify the differential response of glioblastoma multiforme to anti-angiogenic therapy
Shahrzad Jalali et al.
NEURO-ONCOLOGY (2014)
Phase II clinical trial of cediranib in patients with metastatic castration-resistant prostate cancer
William L. Dahut et al.
BJU INTERNATIONAL (2013)
A multi-histology trial of fostamatinib in patients with advanced colorectal, non-small cell lung, head and neck, thyroid, and renal cell carcinomas, and pheochromocytomas
Sook Ryun Park et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2013)
Microvessel density and p53 mutations in advanced-stage epithelial ovarian cancer
Niyati J. Nadkarni et al.
CANCER LETTERS (2013)
Prognostic and Predictive Blood-Based Biomarkers in Patients with Advanced Pancreatic Cancer: Results from CALGB80303 (Alliance)
Andrew B. Nixon et al.
CLINICAL CANCER RESEARCH (2013)
Targeting IL-8 signalling to inhibit breast cancer stem cell activity
Jagdeep K. Singh et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2013)
The role of interleukin-6 in the evolution of ovarian cancer: clinical and prognostic implications-a review
Antonio Maccio et al.
JOURNAL OF MOLECULAR MEDICINE-JMM (2013)
Translational Predictive Biomarker Analysis of the Phase 1b Sorafenib and Bevacizumab Study Expansion Cohort
Nilofer Azad et al.
MOLECULAR & CELLULAR PROTEOMICS (2013)
Clinical value of circulating endothelial cell levels in metastatic colorectal cancer patients treated with first-line chemotherapy and bevacizumab
D. Malka et al.
ANNALS OF ONCOLOGY (2012)
A cytokine and angiogenic factor (CAF) analysis in plasma for selection of sorafenib therapy in patients with metastatic renal cell carcinoma
A. J. Zurita et al.
ANNALS OF ONCOLOGY (2012)
Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors
Junko Murai et al.
CANCER RESEARCH (2012)
Changes in Tumor Blood Flow as Measured by Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) May Predict Activity of Single Agent Bevacizumab in Recurrent Epithelial Ovarian (EOC) and Primary Peritoneal Cancer (PPC) Patients: An exploratory analysis of a Gynecologic Oncology Group Phase II study
Dana M. Chase et al.
GYNECOLOGIC ONCOLOGY (2012)
Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials
Hai T. Tran et al.
LANCET ONCOLOGY (2012)
Evaluation of KRAS Mutations, Angiogenic Biomarkers, and DCE-MRI in Patients with Advanced Non-Small-Cell Lung Cancer Receiving Sorafenib
Ronan J. Kelly et al.
CLINICAL CANCER RESEARCH (2011)
Phase I trial of vandetanib and bevacizumab evaluating the VEGF and EGF signal transduction pathways in adults with solid tumours and lymphomas
Shivaani Kummar et al.
EUROPEAN JOURNAL OF CANCER (2011)
Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study
Karen A. Gelmon et al.
LANCET ONCOLOGY (2011)
Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer
Robert A. Burger et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Optimal treatment for relapsing ovarian cancer
J. A. Ledermann et al.
ANNALS OF ONCOLOGY (2010)
Plasma Cytokine and Angiogenic Factor Profiling Identifies Markers Associated with Tumor Shrinkage in Early-Stage Non-Small Cell Lung Cancer Patients Treated with Pazopanib
Petros G. Nikolinakos et al.
CANCER RESEARCH (2010)
The role of dynamic contrast-enhanced MRI in cancer diagnosis and treatment
Baris Turkbey et al.
DIAGNOSTIC AND INTERVENTIONAL RADIOLOGY (2010)
Distinct Patterns of Cytokine and Angiogenic Factor Modulation and Markers of Benefit for Vandetanib and/or Chemotherapy in Patients With Non-Small-Cell Lung Cancer
Emer O. Hanrahan et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Phase II Trial of Bevacizumab, Thalidomide, Docetaxel, and Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer
Yang-Min Ning et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Inhibition of poly(ADP-ribose) polymerase down-regulates BRCA1 and RAD51 in a pathway mediated by E2F4 and p130
Denise Campisi Hegan et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Cediranib, an Oral Inhibitor of Vascular Endothelial Growth Factor Receptor Kinases, Is an Active Drug in Recurrent Epithelial Ovarian, Fallopian Tube, and Peritoneal Cancer
Ursula A. Matulonis et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Phase 0 Clinical Trial of the Poly (ADP-Ribose) Polymerase Inhibitor ABT-888 in Patients With Advanced Malignancies
Shivaani Kummar et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Histone H2AX is integral to hypoxia-driven neovascularization
Matina Economopoulou et al.
NATURE MEDICINE (2009)
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers.
Peter C. Fong et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Biological and technical variables affecting immunoassay recovery of cytokines from human serum and simulated vaginal fluid: A multicenter study
Raina N. Fichorova et al.
ANALYTICAL CHEMISTRY (2008)
PARP-1 inhibition prevents oxidative and nitrosative stress-induced endothelial cell death via transactivation of the VEGF receptor 2
Marlene T. Mathews et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2008)
Preclinical Modeling of a Phase 0 Clinical Trial: Qualification of a Pharmacodynamic Assay of Poly (ADP-Ribose) Polymerase in Tumor Biopsies of Mouse Xenografts
Robert J. Kinders et al.
CLINICAL CANCER RESEARCH (2008)
Quantification of circulating mature endothelial cells using a whole blood four-color flow cytometric assay
Nathalie Jacques et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2008)
Effect of interleukin-8 gene silencing with liposome-encapsulated small interfering RNA on ovarian cancer cell growth
William M. Merritt et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2008)
Circulating endothelial cells, endothelial progenitor cells, and endothelial microparticles in cancer
P. K. Y. Goon et al.
NEOPLASIA (2006)
Differential effects of vascular endothelial growth factor receptor-2 inhibitor ZD6474 on circulating endothelial progenitors and mature circulating endothelial cells: Implications for use as a surrogate marker of antiangiogenic activity
P Beaudry et al.
CLINICAL CANCER RESEARCH (2005)
Contribution of bone marrow-derived endothelial cells to human tumor vasculature
BA Peters et al.
NATURE MEDICINE (2005)
Cancer of the ovary
SA Cannistra
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Functional tumor imaging with dynamic contrast-enhanced magnetic resonance imaging
PL Choyke et al.
JOURNAL OF MAGNETIC RESONANCE IMAGING (2003)
Ovarian cancer p53 mutation is associated with tumor microvessel density
MJ Goodheart et al.
GYNECOLOGIC ONCOLOGY (2002)
分享论文
